Financial and operating highlights Another strong year for Shire with 12% growth in product sales and 14% growth in Non GAAP earnings which have driven particularly strong cash generation.
2012 highlights Total revenues Initiation of Phase 3 trials for LDX marketed $4,681 as VYVANSE in the US for the treatment of $4,263 negative symptoms of schizophrenia and binge eating disorder: $3,471 Completion of Phase 1 2 trials for HGT2310 for the treatment of Hunter syndrome with CNS symptoms and HGT1410 for Sanlippo A 10% syndrome: 2010 2011 2012 Year on year growth in 2012 Initiation of Phase 3 trials for ABH001 for the treatment of Epidermolysis Bullosa: Non GAAP diluted earnings per ADS Positive outcome from the European $6.10 Decentralised Procedure for ELVANSE $5.34 lisdexamfetamine dimesylate : $4.23 Partnering agreement for VYVANSE and INTUNIV with Shionogi in Japan: Acquisition of FerroKin BioSciences, Inc. bringing global rights to Phase 2 product, 14% SPD602, for treatment of iron overload: 2010 2011 2012 Year on year growth in 2012 Acquisition of Pervasis Therapeutics, Inc.
Non GAAP EBITDA bringing phase 2 product, SRM003 formerly VASCUGEL for hemodialysis access: $1,588 Agreement with Sangamo Biosciences Inc. to $1,478 develop therapeutics for hemophilia and other $1,165 monogenic diseases based on Sangamos zinc nger DNA-binding protein technology.
Lisdexamfetamine dimesylate, active ingredient in VYVANSE ELVANSE 7% 2010 2011 2012 Year on year growth in 2012 2 Shire plc Annual Report 2012 Overview Year on year product growth $M Total revenues by businesses 1 Speciality Pharmaceuticals 61% 1,030 4 28% 3 VYVANSE 2 Human Genetic Therapies 30% 805 3 Regenerative Medicine 3% 498 4 Royalties and other revenues 6% 7% ELAPRASE 2 465 1 498 5% REPLAGAL 475 429 -19% ADDERALL XR 533 400 2012 Cash ow $M 7% LIALDA MEZAVANT 372 Cash generation 1,637 307 20% VPRIV 256 -231 Tax and interest payments 288 INTUNIV 29% -150 Capital expenditure 223 266 Free cash ow 1,256 6% PENTASA 251 -106 Share buy-back 172 3% FOSRENAL 167 -97 Payments for business combinations 154 1 -86 Dividend payment 46% DERMAGRAFT 105 Up-front payments for in-licenses and to -66 116 acquire intangible assets 252% FIRAZYR 33 2 -42 Other investing and nancing 249 -5% OTHER Net cash inow 859 265 2 Other investing and nancing includes purchase of shares by EBT -$99M and 2012 2011 excess tax benefit associated with exercise of stock options $41M.
Product sales for 2012 represent a full year of trading results.
Non GAAP earnings growth 14% By foc cusing on enabling our patients to lead bett ter lives we create greater value for all our stakeholders.
For us, its a neverend ding cycle of increasing value: the mo ore we help our patients, the more value we create for physicians, policy makers, payors, investors and of cou urse our employees who ultimately Value enable us to deliver all this.
